LOGIN  |  REGISTER
Compass Therapeutics

Ionis Pharmaceuticals to present at upcoming investor conferences

February 25, 2025 | Last Trade: US$31.71 1.00 3.26

CARLSBAD, Calif. / Feb 25, 2025 / Business Wire / Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

  • Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025
  • TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025
  • Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025
  • Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025
  • UBS Virtual CNS Day 2025 on Monday, March 17, 2025
  • Stifel 2025 Virtual CNS Forum on Wednesday, March 19, 2025

A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page